GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Cyclically Adjusted PS Ratio

Daiichinkyo Co (Daiichinkyo Co) Cyclically Adjusted PS Ratio : 8.76 (As of May. 02, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Cyclically Adjusted PS Ratio?

As of today (2024-05-02), Daiichinkyo Co's current share price is $33.565. Daiichinkyo Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.83. Daiichinkyo Co's Cyclically Adjusted PS Ratio for today is 8.76.

The historical rank and industry rank for Daiichinkyo Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

DSNKY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.68   Med: 5.17   Max: 9.5
Current: 8.74

During the past years, Daiichinkyo Co's highest Cyclically Adjusted PS Ratio was 9.50. The lowest was 1.68. And the median was 5.17.

DSNKY's Cyclically Adjusted PS Ratio is ranked worse than
91.01% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs DSNKY: 8.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Daiichinkyo Co's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.490. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.83 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Daiichinkyo Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Daiichinkyo Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Cyclically Adjusted PS Ratio Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.17 6.74 5.45 9.22 8.30

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.22 8.55 7.56 6.99 8.30

Competitive Comparison of Daiichinkyo Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Cyclically Adjusted PS Ratio falls into.



Daiichinkyo Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Daiichinkyo Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=33.565/3.83
=8.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Daiichinkyo Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.49/107.2000*107.2000
=1.490

Current CPI (Mar. 2024) = 107.2000.

Daiichinkyo Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.990 98.000 1.083
201409 0.950 98.500 1.034
201412 1.049 97.900 1.149
201503 0.883 97.900 0.967
201506 0.913 98.400 0.995
201509 0.966 98.500 1.051
201512 1.119 98.100 1.223
201603 0.982 97.900 1.075
201606 1.113 98.100 1.216
201609 1.051 98.000 1.150
201612 1.192 98.400 1.299
201703 0.980 98.100 1.071
201706 1.081 98.500 1.176
201709 1.042 98.800 1.131
201712 1.209 99.400 1.304
201803 1.053 99.200 1.138
201806 1.053 99.200 1.138
201809 1.013 99.900 1.087
201812 1.172 99.700 1.260
201903 1.047 99.700 1.126
201906 1.184 99.800 1.272
201909 1.100 100.100 1.178
201912 1.306 100.500 1.393
202003 1.072 100.300 1.146
202006 1.131 99.900 1.214
202009 1.183 99.900 1.269
202012 1.281 99.300 1.383
202103 1.068 99.900 1.146
202106 1.250 99.500 1.347
202109 1.258 100.100 1.347
202112 1.287 100.100 1.378
202203 1.028 101.100 1.090
202206 1.091 101.800 1.149
202209 1.191 103.100 1.238
202212 1.315 104.100 1.354
202303 1.288 104.400 1.323
202306 1.294 105.200 1.319
202309 1.324 106.200 1.336
202312 1.618 106.800 1.624
202403 1.490 107.200 1.490

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Daiichinkyo Co  (OTCPK:DSNKY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Daiichinkyo Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.